Basic↦Quality and Risk↦Quality Responsibilities↦Sponsor-Investigator
What is it? Why is it important?
The Sponsor-Investigator (SP-INV) is legally responsible to ensure the:
To achieve this, a risk-based Quality Management System (QMS), including Quality Assurance (QA) and Quality Control (QC) procedures must be in place.
Key elements of a risk-based approach include to:
- Define the Critical to Quality (CtoQ) factors of the study
- Identify risks that threaten the integrity of CtoQ factors
- Evaluate and prioritise risks (i.e. according to a risk-evaluation-matrix that correlates and assesses the likelihood of risk occurrence with risk impact on CtoQ factors)
- Decide, based on risk evaluation & prioritisation, whether to accept, tolerate, reduce, or eliminate risks
- Define risk control-measures proportionate to the importance of the data being collected, and safety risks to study participant
- Defines roles and risk responsibilities
- Train staff on risk management and risk responsibilities
- Continuously review and document risk events and the adjustments of risk control-measures
What do I need to do?
As a SP-INV, you are responsible to protect study participants and generate study data able to answer the research question.
To achieve this:
- Apply a “Quality-by-Design” (QbyD) approach to your study, with the aim is to manage risks before they occur
- Implement a Risk-Based Quality Management System (QMS), focusing on potential risks threatening the integrity of the study`s CtoQ factors
- When defining CtoQ factors, focus on participant rights and safety (e.g. risk-benefit-ratio), and the quality of study data
- In a multicentre study, consider regional or local settings. Confer with the Site-INV to identify local risks and quality aspects in need of management
- Confer with experts supporting the identification of risks to CtoQ factors (e.g. study staff, statistician, quality manager)
- Define applicable risk control-measures
- Document the risk management of the study in a Risk Assessment Form (RAT)
- Maintain and update risk management documents throughout the study, reflecting changes in risk assessment or control
More
Study aim and design should be tailored based on the information needed to answer your research question. The complexity of your study (e.g. design, population) will have a significant effect on potential inherent risks, and the required risk-based-approach needed to control these risks.
Excessive activities beyond requirements can overburden staff, extend study milestones and timelines, increase the budget, and the occurrence of risks. Align quality activities proportionally to trial complexity and defined CtoQ factors.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guideline
- 2.3 responsibilities
- 3.10 Quality management
ICH E8(R1) – see in particular
- 3.1 Quality by Design of clinical studies
- 3.2 Critical to Quality Factors
ISO 31000 – (access liable to costs) see in particular section
- Risk management: Principles and guidelines
Swiss Law
ClinO – see in particular article
- Art. 2 Definitions
Documents